INTERCEPT PHARMACEUTICALS, INC. (NASDAQ:ICPT) Files An 8-K Other EventsItem 8.01. Other Events.
Intercept Pharmaceuticals, Inc. is shifting guidance for an announcement of the Phase 3 REVERSE trial in NASH patients with compensated cirrhosis from YE17 to 1Q18.
About INTERCEPT PHARMACEUTICALS, INC. (NASDAQ:ICPT)
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is developing OCA for the treatment of liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic steatoheptitis (NASH), primary sclerosing cholangitis (PCS) and biliary atresia. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.
